11:40 uur 08-01-2016

Sinocare Group voltooit overname Nipro Diagnostics

FT. LAUDERDALE, Fla.–(BUSINESS WIRE)– Nipro Diagnostics heeft vandaag bekendgemaakt dat zijn overname door de Sinocare Group is voltooid. Het bedrijf maakt bovendien bekend dat het voortaan de naam Trividia Health draagt. Scott Verner, die bestuursvoorzitter, ceo en president van Nipro Diagnostics was, is benoemd tot ceo en president van Trividia Health. Belangrijke leidinggevenden uit zijn huidige team blijven hem bijstaan. Het bedrijf blijft gevestigd in de Verenigde Staten.

“Net zoals Sinocare behelst de langetermijnvisie van Nipro Diagnostics een toonaangevend, mondiaal bedrijf in de gezondheidszorg dat innovatieve en waardevolle oplossingen aandraagt, zodat patiënten gezonder leven”, zei Shaobo Li, bestuursvoorzitter en ceo van Sinocare. “We hebben veel respect voor dat wat het bestuur en personeel van Nipro Diagnostics hebben bereikt. We hebben veel vertrouwen in hun vermogen onze gedeelde visie te versnellen. Samen wordt ons portfolio van producten en diensten, onze koers en ons grote vertrouwen in de mensen die onze producten en diensten vormgeven, produceren en verkopen van vitaal belang voor het bereiken van onze gedeelde doelstellingen.”

 

Sinocare Group Closes Acquisition of Nipro Diagnostics

FT. LAUDERDALE, Fla.–(BUSINESS WIRE)– Nipro Diagnostics announced today that its acquisition by Sinocare Group has been completed. The company also announced that with completion of the acquisition, the company has been renamed Trividia Health. Scott Verner, who was Chairman, CEO and President of Nipro Diagnostics, has been named CEO and President of Trividia Health and will be joined by key executives from his current management team. The company will remain in the United States.

“Like Sinocare, Nipro Diagnostics has the long-term vision of being a leading global health and wellness company that offers innovative, high-value solutions so patients can live healthier lives,” Sinocare Chairman and CEO Shaobo Li said. “We have a great deal of respect for what the management team and employees have accomplished at Nipro Diagnostics, and we are confident in their ability to accelerate our shared vision. Joined together, our proven portfolio of products and services, our combined future direction and our strong confidence in the people who design, manufacture and sell our products and services, will be vital to attaining our shared goals.”

“Our company has experienced strong growth as a result of our new product launch cadence and our investments in highly sophisticated manufacturing and distribution facilities in the United States. This is an exciting next chapter for our combined company. I’m proud to have led the company through many changes in the public and private markets. I look forward to maximizing the global potential of our portfolio of solutions for patients, healthcare providers and our customers,” said Trividia Health CEO Scott Verner.

The new name, Trividia Health, signals the company’s new trajectory and represents the values, vision and market of the global enterprise. “TRI” honors Sinocare’s three commitments to customers, employees and shareholders; “VI” stands for the commitment to patient victory over diabetes and other health challenges; and “DIA” refers to the company’s core diabetes foundation. Finally, HEALTH was added to the name to signal the company’s new focus on developing integrated health solutions beyond diabetes.

About Trividia Health

Trividia Health, Inc., a wholly owned subsidiary of Sinocare Group, is a global health and wellness company based in Fort Lauderdale, Florida and a leading developer, manufacturer and marketer of advanced performance products for people with diabetes. With products sold under TRUE and store brand labels, the company is the exclusive partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for the world’s leading retail pharmacies, distributors and mail service providers. For more information, please visit:  www.TrividiaHealth.com.

About Sinocare Group

Sinocare Group consists of Sinocare, Inc., Sinocare Jianheng Diabetes Hospital, and its affiliates. Sinocare Inc., headquartered in Changsha, China, is fully dedicated to the innovation of biosensor technology, promoting diabetic self-management by using blood glucose monitoring systems, providing total diabetes services and solutions in China. Founded in 2002 and listed on the Shenzhen Stock Exchange (SHE:300298) in 2012, the company has been providing high quality and low cost blood glucose monitoring systems to the Chinese market and has been listed by Forbes as one of Asia’s 200 Best Under a Billion companies.

Contacts

Trividia Health
Neal Bhattacharya, 1-800-342-7226 ext. 3150
nbhattacharya@niprodiagnostics. com

 

Check out our twitter: @NewsNovumpr